Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity MOST POPULAR Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 Καρκίνος Δέρματος January 20, 2019 EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel May 27, 2022 First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... July 26, 2022 Load more HOT NEWS ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk... Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... Woman Helps Students With Special Needs Achieve Success After Graduation
